Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
Pacira BioSciences presented real-world study findings at ISPOR 2026 showing EXPAREL use was associated with reduced opioid consumption and lower healthcare costs in patients undergoing total shoulder arthroplasty. The retrospective analysis covered more than 6,400 opioid-naïve Medicare Advantage patients, comparing EXPAREL against standard-of-care analgesia using data from Optum Clinformatics.
Key figures
- Study population size
- 6400
- Opioid consumption reduction
- 78%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.